Progress with the polypill?

JAMA

Volumn 310, Issue 9, 2013, Pages 910-911

  Gaziano, J Michael ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS LISINOPRIL PLUS SIMVASTATIN; CARDIAC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDITORIAL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 84883391061     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.277066     Document Type: Editorial

References (9)

1. European patent specification: formulation for the prevention of cardiovascular disease. EP 1 272 220 B1. Proprietors Wald NJ, Law MR; priority 10.04.2000.
2. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419-1423. (Pubitemid 36776151)
3. Yusuf S, Pais P, Afzal R, et al Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors inmiddle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341-1351.
4. Rodgers A, Patel A, Berwanger O, et al PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One. 2011;6(5):e19857.
5. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ("polypill") on cardiovascular risk factors. Int J Clin Pract. 2010;64(9):1220-1227.
6. Wald DS, Morris JK, Wald NJ. Randomized Polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7):e41297.
7. Soliman EZ, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of theWorld Health Organization. Trials. 2011;12(1):3.
8. Elley CR, Gupta AK,Webster R, et al. The efficacy and tolerability of "polypills": meta-analysis of randomised controlled trials. PLoS One. 2012;7(12):e52145.
9. Thom S, Poulter N, Field J, et al UMPIRE Collaborative Group. Effects of a fixed-dose combination on medication adherence and risk factors in patients with or at risk of CVD: the UMPIRE randomized clinical trial. JAMA. doi:10.1001/jama.2013.277064.